SINTX Technologies, Inc. signed a supply agreement with Evonik Corporation to manufacture a silicon nitride-PEEK compound for patient-specific implants.
The agreement enables immediate production of AI-assisted, 3D-printed patient-specific implants using SINTX's U.S.-based facility.
The proprietary SiN/PEEK compound offers advantages over standard PEEK, including antipathogenic properties and improved visualization features.
SiN/PEEK Compound Supply Agreement
SINTX signed an agreement with Evonik to produce a unique compound for patient-specific implants.
Impact on Manufacturing
The agreement allows SINTX to begin manufacturing AI-designed, 3D-printed implants immediately.
Material Advantages
SiN/PEEK offers antipathogenic surface behavior, osteogenic support, and enhanced visualization during procedures.
- The supply agreement with Evonik positions SINTX to address critical needs in trauma, spine, oncology, and beyond.
- SiN/PEEK compound's attributes aim to improve medical outcomes, providing design freedom and scalability for patient-specific geometries.
The collaboration between SINTX Technologies and Evonik Corporation marks a significant advancement in the production of patient-specific implants with enhanced features. The SiN/PEEK compound is poised to make a positive impact on medical device innovation and patient care.